Overview

Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy

Status:
Unknown status
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This prospective, randomized, controlled, multi-center clinical trial will evaluate the effect and security of reh-acteoside therapy for patients of IgA nephropathy.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Acteoside
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate